NCT00002385

The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients

Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (planned)
• Sponsor: Anderson Clinical Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To identify doses of fozivudine tidoxil that are well tolerated and produce measurable antiviral activity. To identify the adverse event profile that defines the maximum tolerated dose. To characterize the single- and multiple-dose pharmacokinetics of fozivudine and its metabolites. To correlate the adverse event profile and antiviral activity of fozivudine with pharmacokinetic parameters.

Detailed description

In this double-blind, dose-escalating study, patients receive fozivudine tidoxil at one of 5 dosage levels for 4 weeks and are randomized with respect to once- or twice-daily administration (cohorts 2 vs. 3 and 4 vs. 5). Within each cohort, 10 patients are randomized to the study drug and 2 to the placebo. At least 9 of the 12 patients enrolled in Cohort 1 must complete the entire 4-week course before Cohorts 2 and 3 are enrolled. At least 18 of these 24 patients must complete 2 weeks of the 4-week course before Cohorts 4 and 5 are enrolled.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Fozivudine tidoxil

Timeline

• First posted: 2001-08-31
• Last updated: 2005-06-24